GlaxoSmithKline drug for Crohn's flops in study, partner ChemoCentryx's stock plunges
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline said an experimental drug for the inflammatory bowel condition Crohn’s disease failed to meet its goals in a late-stage study.